{'fraction_non_alphanumeric': 0.03588516746411483, 'fraction_numerical': 0.027910685805422646, 'mean_word_length': 5.370558375634518, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association of Betatrophin, TNF- and #945; and IL-6 with diabetic microvascular and macrovascular complications

Aim: The most important goal in the treatment of Diabetes Mellitus is to protect patients from micro and macro complications. Inflammatory cytokines and betatrophin have been reported to play a role in diabetic micro and macro complications. This study aimed to investigate the effect of serum Betatrophin, TNF-α and IL-6 levels on diabetic micro and macro complications in patients with type 2 Diabetes Mellitus. 
Materials and Methods: This case-control study was conducted with 91 type 2 Diabetes Mellitus (T2DM) patients between January-December 2018. Case series with 91 patients divided into three groups were included; 31 T2DM patients without diabetic complications (group 1=control), 30 patients with diabetic microvascular complications (group 2) and 30 patients with diabetic macrovasculer complications (group 3). Blood was collected to evaluate biochemical parameters, TNF-α, IL-6 and betatrophin. 
Results: Betatrophin level was high in patients with renitopathy (p=0.042) and diabetic foot (p=0.036). TNF-α levels were higher in patients with both microvascular and macrovascular complications compared to the control group (p